

ABSTRACT OF THE DISCLOSURE

Novel process to manufacture omega form and form-II of anhydrous Gatifloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-piperazinyl)-3-guinodine carboxylic acid) having structural formula (I) is disclosed. The invention does not require high temperature or use of column chromatography for purification. Moreover the solvents being used in the process can be recovered and recycled. These factors make the process industrially efficient.